| I-07 Yumi Yamamoto Development of a generic model for brain distributional pharmacokinetics and its translation to clinical data Wednesday 10:20-11:40 |
| I-08 Gregory Ferl Mechanistic model of amyloid beta (Aß) and anti-Aß mAb dynamics Wednesday 10:20-11:40 |
| I-13 Nicolas Frey Model-based meta-analysis of amyloid plaque reduction in Alzheimer’s disease patients to identify new Phase 3 doses and dosing regimens for Gantenerumab Wednesday 10:20-11:40 |
| I-58 Marija Jovanovic Population pharmacokinetic model of topiramate and its major metabolite in adult epileptic patients Wednesday 10:20-11:40 |
| I-60 Tatiana Karelina Clinical trial simulation and hypothesis testing using amyloid pathology longitudinal translational model Wednesday 10:20-11:40 |
| I-69 Max Lagraauw A population disease progression model for Amyotrophic Lateral Sclerosis – Results of the Treeway Summer Challenge 2015 Wednesday 10:20-11:40 |
| I-73 Mary Lavy Population Pharmacokinetics (PK) and Pharmacodynamics (PD) of Natalizumab in Patients with Multiple Sclerosis (MS) Wednesday 10:20-11:40 |
| II-03 Malidi Ahamadi Population exposure –response analysis of “On-Off” time in Individuals with Parkinson Disease following Preladenant Treatment Wednesday 15:10-16:30 |
| II-08 Silvana Alvariza Autoinduction of phenytoin hepatobiliary secretion as a mechanism for its nonlinear pharmacokinetics Wednesday 15:10-16:30 |
| II-26 Irina Bondareva External validation and predictability of nonlinear models for changes in steady–state pharmacokinetics (PK) of carbamazepine (CBZ) and valproate (VPA) due to antiepileptic drug-drug interactions using sparse therapeutic drug monitoring (TDM) data Wednesday 15:10-16:30 |
| II-53 Valerie Cosson Amyloid related imaging abnormalities (ARIA): Time to event modeling to identify new Phase 3 doses and dosing regimens for Gantenerumab Wednesday 15:10-16:30 |
| II-58 Fabrizia D'Antonio Effect of psychotic subtypes on cognitive trajectories in Alzheimer’s disease Neuroimaging Initiative ADNI2. Wednesday 15:10-16:30 |
| III-03 Andreas Lindauer Time-to-seizure modeling of the antiepileptic drug lacosamide used in monotherapy Thursday 10:05-11:30 |
| III-16 Amelie Marsot Population pharmacokinetic model of delta-9-tetrahydrocannabinol (THC) in cannabis occasional smokers Thursday 10:05-11:30 |
| III-43 Theodoros Papathanasiou Population modelling of the synergistic effects of morphine and gabapentin in the rat: a response surface approach Thursday 10:05-11:30 |
| III-66 Su-jin Rhee A population pharmacokinetic analysis of levetiracetam in patients with epilepsy Thursday 10:05-11:30 |
| IV-20 Eva Sverrisdottir Pharmacokinetic Metamodel of Morphine and Morphine-6-Glucuronide in Neonates and Adults Thursday 14:40-16:00 |
| IV-23 Paulo Teixeira The Effect of Anthropometric Covariates on Clearance of Valproic Acid. Thursday 14:40-16:00 |
| IV-36 Iñaki F. Trocóniz Markov Model for Lithium Compliance Assessment Thursday 14:40-16:00 |
| IV-37 Max Tsai Modelling of Pharmacokinetics and the Incidence of Adverse Events of the PDE-10A Inhibitor TAK-063 Thursday 14:40-16:00 |
| IV-44 Sven van Dijkman Differentiation between Parkinson’s and Parkinson’s-like patients in MDS-UPDRS-based diagnosis Thursday 14:40-16:00 |
| IV-69 Seonghae Yoon Population pharmacokinetic analysis of oxcarbazepine in patients with epilepsy Thursday 14:40-16:00 |
